Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. THIS QUARTER, WE CONTINUED TO EXECUTE ACROSS A DIVERSE PIPELINE SPANNING MULTIPLE, POTENTIALLY HIGH IMPACT PROJECTS IN INFECTIOUS DISEASES AND ONCOLOGY, LEVERAGING OUR BORON CHEMISTRY PLATFORM TO AD.

AN2 THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY ADVANCING NOVEL SMALL MOLECULE THERAPEUTICS THROUGH ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED A COLLABORATION AGREEMENT WITH THE GLOBAL BIOPHARMA COMPANY GSK TO DEVELOP NEW THERAPIES FOR TUBERCULOSIS (TB). AS PART OF THIS EFFORT, THE GATES FOUNDATION WILL PROVIDE A THIRD YEAR OF FUNDING TO SUPPORT AN2'S WORK WITHIN THE COLLABORATION. TB CONTINUES TO POSE A MAJOR GLOBAL HEALTH CHALLENGE, A.

AN2 THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION WITH GSK TO ADVANCE BORON-BASED LEURS-INHIBITORS TARGETING TUBERCULOSIS (TB)

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND CEO, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 8TH ANNUAL EVERCORE HEALTHCONX CONFERENCE BEING HELD FROM DECEMBER 2-4, 2025. DETAILS OF THE EVENT ARE AS FOLLOWS: ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND.

AN2 THERAPEUTICS TO PARTICIPATE IN FIRESIDE CHAT AT EVERCORE HEALTHCONX CONFERENCE

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT IT HAS COMPLETED DOSING THE FIRST SINGLE ASCENDING DOSE COHORT IN ITS PHASE 1 FIRST-IN-HUMAN CLINICAL TRIAL EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL AN2-502998 IN HEALTHY VOLUNTEERS. AN2-502998 IS A POTENTIALLY CURATIVE DRUG CANDIDATE FOR CHRONIC.

AN2 THERAPEUTICS COMMENCES FIRST-IN-HUMAN CLINICAL TRIAL OF ORAL AN2-502998 FOR CHAGAS DISEASE

MENLO PARK, CALIF. & GENEVA--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX) AND THE NON-PROFIT MEDICAL RESEARCH ORGANIZATION DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI) TODAY ANNOUNCED A COLLABORATION TO ADVANCE CLINICAL DEVELOPMENT OF AN2-502998, AN2'S ORAL DRUG CANDIDATE IN DEVELOPMENT FOR THE TREATMENT OF CHRONIC CHAGAS DISEASE. CHAGAS DISEASE IS A LIFE-THREATENING DISEASE CAUSED BY THE PARASITE TRYPANOSOMA CRUZI AND AFFECTS 6 TO 7 MILLION PEOPLE WORLDWIDE, INCLUDING AN ESTIMATED.

AN2 THERAPEUTICS AND DNDI COLLABORATE ON CLINICAL DEVELOPMENT OF PROMISING NEW ORAL COMPOUND TO TREAT CHRONIC CHAGAS DISEASE

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THE COMPLETION OF A 200-PATIENT OBSERVATIONAL STUDY IN ACUTE MELIOIDOSIS, A HIGHLY LETHAL BACTERIAL INFECTION AND RECOGNIZED BIOTHREAT. THE STUDY, CONDUCTED UNDER REAL-WORLD CONDITIONS IN ACUTE HOSPITAL SETTINGS, EVALUATED PATIENTS RECEIVING THE CURRENT STANDARD OF CARE (SOC).

AN2 THERAPEUTICS REPORTS KEY INSIGHTS FROM 200-PATIENT OBSERVATIONAL STUDY IN ACUTE MELIOIDOSIS, LAYING GROUNDWORK FOR PHASE 2 PROOF-OF-CONCEPT TRIAL OF EPETRABOROLE

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT A POSTER HIGHLIGHTING THE PRECLINICAL ACTIVITY OF EPETRABOROLE AGAINST M. ABSCESSUS ON THURSDAY, MAY 29, 2025 AT THE NONTUBERCULOUS MYCOBACTERIA CONFERENCE TO BE HELD MAY 27-30, 2025 AT COLORADO STATE UNIVERSITY. IT IS ESTIMATED THAT.

AN2 THERAPEUTICS ANNOUNCES POSTER PRESENTATION HIGHLIGHTING M. ABSCESSUS DATA AT 2025 COLORADO MYCOBACTERIA CONFERENCE

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. AS WE LOOK AHEAD TO THE REMAINDER OF 2025, WE ARE POISED TO ADVANCE OUR PIPELINE LEVERAGING OUR BORON CHEMISTRY PLATFORM, WHICH HAS THE POTENTIAL TO ADDRESS SERIOUS UNMET NEEDS OF PATIENTS. WE HAVE HIGH.

AN2 THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2024. "EPETRABOROLE DEMONSTRATED POTENTIAL PROOF-OF-CONCEPT IN PHASE 2, ACHIEVING NOMINAL STATISTICAL SIGNIFICANCE ON TWO PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH TREATMENT-REFRACTORY MA.

AN2 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DISCOVERING AND DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND CEO, WILL PRESENT AT THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE. DETAILS OF THE EVENT ARE AS FOLLOWS: LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND CEO, WIL.

AN2 Therapeutics, Inc.

ANTX

Price

Financial Reports

No items found.

Press Releases

AN2 Therapeutics, Inc.

ANTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ANTX